Evidence map›Paper›PMID 27532118›Full record

ArticleInternational braz j urol : official journal of the Brazilian Society of Urology

Long term outcome and side effects in patients receiving low-dose I125 brachytherapy: a retrospective analysis.

Pieter Logghe, Rolf Verlinde, Frank Bouttens, Caroline Van den Broecke, Nathalie Deman, Koen Verboven, Dirk Maes, Luc Merckx

Open access · diamondAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Success ofOncoTargets and therapy · 2020
    Article
  3. Review
  4. Review
  5. Article
  6. A Case of Iodine 125 Seeds (I-125) Responding to Lung Squamous Cell Carcinoma.Dose-response : a publication of International Hormesis Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Pieter LoggheDepartment of Urology, AZ St Lucas, Ghent, Oost-Vlaanderen, Belgium.
Rolf VerlindeDepartment of Urology, AZ St Lucas, Ghent, Oost-Vlaanderen, Belgium.
Frank BouttensDepartment of Radiotherapy-Oncology, AZ St Lucas, Ghent, Oost-Vlaanderen, Belgium.
Caroline Van den BroeckeDepartment of Pathology, AZ St Lucas, Ghent, Oost-Vlaanderen, Belgium.
Nathalie DemanDepartment of Physics, AZ St Lucas, Ghent, Oost-Vlaanderen, Belgium.
Koen VerbovenDepartment of Physics, AZ St Lucas, Ghent, Oost-Vlaanderen, Belgium.
Dirk MaesDepartment of Urology, AZ St Lucas, Ghent, Oost-Vlaanderen, Belgium.
Luc MerckxDepartment of Urology, AZ St Lucas, Ghent, Oost-Vlaanderen, Belgium.
AZ Sint-Lucas · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo retrospectively evaluate the disease free survival (DFS),disease specific survival (DSS),overall survival (OS) and side effects in patients who received low-dose rate (LDR) brachytherapy with I125 stranded seeds. MATERIALS AND

methodsBetween july 2003 and august 2012, 274 patients with organ confined prostate cancer were treated with permanent I125 brachytherapy. The median follow-up, age and pretreatment prostate specific antigen (iPSA) was 84 months (12-120), 67 years (50-83) and 7.8 ng/mL (1.14-38), respectively. Median Gleason score was 6 (3-9). 219 patients (80%) had stage cT1c, 42 patients (15.3%) had stage cT2a, 3 (1.1%) had stage cT2b and 3 (1.1%) had stage cT2c. The median D90 was 154.3 Gy (102.7-190.2).

resultsDSS was 98.5%.OS was 93.5%. 13 patients (4.7%) developed systemic disease, 7 patients (2.55%) had local progression. In 139 low risk patients, the 5 year biochemical freedom from failure rate (BFFF) was 85% and 9 patients (6.4%) developed clinical progression. In the intermediate risk group, the 5 year BFFF rate was 70% and 5 patients (7.1%) developed clinical progression. Median nPSA in patients with biochemical relapse was 1.58 ng/mL (0.21 - 10.46), median nPSA in patients in remission was 0.51 ng/mL (0.01 - 8.5). Patients attaining a low PSA nadir had a significant higher BFFF (p<0.05). Median D90 in patients with biochemical relapse was 87.2 Gy (51 - 143,1). Patients receiving a high D90 had a significant higher BFFF (p<0.05).

conclusionIn a well selected patient population, LDR brachytherapy offers excelente outcomes. Reaching a low PSA nadir and attaining high D90 values are significant predictors for a higher DFS.

Indexed as

AgedAged, 80 and overBrachytherapyDose-Response Relationship, RadiationHumansIodine RadioisotopesLogistic ModelsMaleMiddle AgedPrognosisProstate-Specific AntigenProstatic NeoplasmsRectumRetrospective StudiesRisk AssessmentRisk FactorsIodine RadioisotopesProstate-Specific AntigenBrachytherapyProstate-Specific AntigenProstatic Neoplasms

Identifiers

PMID27532118
PMCPMC5066886
OpenAlexW2515076728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.